

# JCOG 0702

## A PHASE I DOSE ESCALATION STUDY OF SBRT IN PATIENTS WITH T2N0M0 NON-SMALL CELL LUNG CANCER

- ✓ To define the recommended dose of SBRT for T2N0M0 NSCLC
- ✓ Primary endpoint, Grade  $\geq 2$  pneumonitis
- ✓ Sample size, 60+ pts (CRM)
  - Inoperable or 'unfit' for surgery
  - Accrual: 5 years

# JCOG 0702

## A PHASE I DOSE ESCALATION STUDY OF SBRT IN PATIENTS WITH T2N0M0 NON-SMALL CELL LUNG CANCER

### ✓ Eligibility

- Pathologically proven NSCLC
- Stage IB
- Medically inoperable or unfit
- PS 0-2
- $\text{PaO}_2 \geq 60$  torr
- $\text{FEV}_{1.0} \geq 700$  ml
- Written informed consent

# JCOG 0702

## A PHASE I DOSE ESCALATION STUDY OF SBRT IN PATIENTS WITH T2N0M0 NON-SMALL CELL LUNG CANCER

### ✓ Treatment

-4-6 MV X rays

-40-65 Gy in 4 fractions over 4-8 days

-prescribed to  $D_{95}$  of the PTV

-heterogeneity corrected dose

-algorithm, superposition